Post by JHam on Jul 25, 2014 7:07:53 GMT
It looks like BCLI just secured a $5M grant from the Ministry of Health in Brazil. I don't have the link yet, but the following was just posted by a reliable poster in Yahoo who has posting news from Israel in the past. This is the Hebrew translation (incomplete). I'll post the link when I get it:
Brainstorm cell will receive a grant of $ 5 million from the Ministry of Health in Brazil, testing the product in its collaboration with the University of San Paulo, the sources added. "The company declined to comment.
Brainstorm has $ 3 million in the fund as of the end of the first quarter of 2014, and its market cap is $ 78 million.
A month ago, the Company completed a $ 10.5 million private placement. The issue price of $ 0.25 per share, then a 15% discount on the price in the market, and investors also received stock options at an exercise price of 0.348 dollars. These options are already in the money because the stock traded at $ 0.35.
The current amount of a grant to be used there is no need to return solely for the purpose experiment Moore now treat ALS, a fatal muscle wasting disease. At the same time Breinsorm been conducting a Phase IIa product versus the FDA, the Food and Drug Administration. The Company also operates upgrade Nasdaq trading. Currently trading on the OTC.
Brainstorm president and largest shareholder which is a life Leibowitz, owner of ACC, which was the first investor B"shmn "(and out has yet to decline). Leibowitz holds about 20% of the company after the IPO.
Brainstorm also announced today the development of the construction of its production process: Complete Bio - Reactor (a tool biological substances react with each other) commercial production of stem cells are used as the basis for its treatment in ALS. To increase stem cells requires special manufacturing environment is critical to the success of treatment. Bio - Reactor wa
Brainstorm cell will receive a grant of $ 5 million from the Ministry of Health in Brazil, testing the product in its collaboration with the University of San Paulo, the sources added. "The company declined to comment.
Brainstorm has $ 3 million in the fund as of the end of the first quarter of 2014, and its market cap is $ 78 million.
A month ago, the Company completed a $ 10.5 million private placement. The issue price of $ 0.25 per share, then a 15% discount on the price in the market, and investors also received stock options at an exercise price of 0.348 dollars. These options are already in the money because the stock traded at $ 0.35.
The current amount of a grant to be used there is no need to return solely for the purpose experiment Moore now treat ALS, a fatal muscle wasting disease. At the same time Breinsorm been conducting a Phase IIa product versus the FDA, the Food and Drug Administration. The Company also operates upgrade Nasdaq trading. Currently trading on the OTC.
Brainstorm president and largest shareholder which is a life Leibowitz, owner of ACC, which was the first investor B"shmn "(and out has yet to decline). Leibowitz holds about 20% of the company after the IPO.
Brainstorm also announced today the development of the construction of its production process: Complete Bio - Reactor (a tool biological substances react with each other) commercial production of stem cells are used as the basis for its treatment in ALS. To increase stem cells requires special manufacturing environment is critical to the success of treatment. Bio - Reactor wa
